$1.79
arrow_drop_up5.95%Key Stats | |
---|---|
Open | $1.69 |
Prev. Close | $1.68 |
EPS | -0.84 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $49.23M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.58 | 1.79 |
52 Week Range | 1.26 | 7.75 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -0.84 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 - GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma on Track to Dose NXC-201 Patients in United States